Trial Profile
A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2020
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Proof of concept
- Sponsors Incyte Corporation
- 01 Jan 2019 Status changed to discontinued.
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
- 03 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.